The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer

Area of Science:

• Onco-immunology
• Cancer Metabolism

Background:

• Pancreatic ductal adenocarcinoma (PDA) is highly lethal with limited treatment options.
• Cancer cells exhibit altered glucose metabolism, particularly in hypoxic tumor microenvironments.
• This metabolic shift promotes tumor progression and creates an immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

• To review the role of glycolytic enzymes in PDA progression and metastasis.
• To explore the potential of targeting these enzymes as novel therapeutic strategies.
• To discuss the exploitation of glycolytic enzymes as immunological targets in anti-PDA therapies.

Main Methods:

• Literature review of genetic background and emerging glycolytic enzymes in PDA.
• Analysis of metabolic reprogramming in PDA cells.
• Investigation of immune responses to overexpressed or mutated glycolytic enzymes.

Main Results:

• PDA cells exhibit increased glucose uptake and glycolysis, leading to lactate accumulation.
• Acidification of the TME due to lactate impairs anti-tumor immunity.
• Overexpressed or mutated glycolytic enzymes can stimulate humoral and cellular immune responses.

Conclusions:

• Targeting glycolytic enzymes represents a feasible therapeutic strategy for PDA.
• Exploiting glycolytic enzymes as immunological targets holds promise for novel anti-PDA treatments.
• Understanding metabolic reprogramming is crucial for developing effective pancreatic cancer therapies.